AlloEx exosomes
Phase 1
AlloEx exosomes is one of 6 therapeutic programs targeting Congenital Myasthenic Syndrome. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Congenital Myasthenic Syndrome
#DrugCompanyPhaseTrials
1Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Approved
Adimanebart IV
ArgenxPhase 3
Alloex
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
ARGX-119
ArgenxPhase 1
AlloEx exosomes
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
Firdapse
CCatalyst Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Congenital Myasthenic Syndrome1 trial
Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07226726·20 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for AlloEx exosomes. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]